Foxo Technologies INC 10-Q quarterly reports

FOXO Technologies Inc. reported a net loss of $1.5 million for the first quarter of 2026, with revenues increasing by 63% to $5.2 million.

FOXO Technologies reported a significant revenue increase in Q3 2025 driven by recent acquisitions, but faces ongoing delisting from NYSE American, substantial losses to common stockholders, and a going concern doubt.

FOXO Technologies Inc. reported a significant revenue increase in Q2 2025 driven by recent healthcare acquisitions, but faces substantial doubt about its going concern ability and delisting from NYSE American.

FOXO Technologies Inc. has restated its first-quarter 2025 financial statements due to an accounting error related to a recent acquisition, revealing a significantly increased working capital deficit and continued substantial doubt about its ability to continue as a going concern.

FOXO Technologies' Q1 2025 results show a shift towards healthcare with significant revenue from recent acquisitions, alongside ongoing efforts to manage debt and improve financial stability.

FOXO Technologies' third quarter 2024 results reflect the impact of recent acquisitions in the healthcare sector, alongside ongoing developments in its Labs and Life segment.

FOXO Technologies' second quarter 2024 results show a decrease in net loss and the acquisition of Myrtle Recovery Centers, impacting both revenue and expenses.

FOXO Technologies secured a $750,000 loan while reporting a net loss of $2.16 million for Q1 2024, highlighting ongoing financial difficulties and strategic shifts.

FOXO Technologies Inc. has restated its financial statements for the three and nine months ended September 30, 2023, due to an error in accounting for down round provisions of assumed warrants.

FOXO Technologies reported a net loss of $3.66 million for Q3 2023, as the company navigates financial difficulties and strategic shifts.